TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ:TOMZ), a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide (iHP), is pleased to showcase a highly-valued customer relationship with Merakey Behavioral Health. Merakey provides education, support a
BEVERLY HILLS, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ:TOMZ), a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide (iHP), is pleased to showcase a highly-valued customer relationship with Merakey Behavioral Health.
Merakey provides education, support and therapy services in the areas of intellectual and developmental disability, behavioral health, autism, and addiction recovery to children and adults. It has locations in 12 states with a heavy concentration throughout Pennsylvania, placing great confidence in the SteraMist technology to safeguard their staff and patients in several facilities. TOMI’s Service Network (TSN) member, Enviro-Mist, utilizes SteraMist technology to treat 234,582 square feet across five Merakey campuses in Southeastern Pennsylvania on a quarterly basis.
Additionally, Merakey operations personnel treat their own facilities using five TOMI SteraMist Surface Unit disinfection devices, one for each facility. Merakey routinely treats more frequently with their units, as well as providing spot disinfection for suspected COVID-positive exposure and high traffic areas. These areas include common areas, dining areas, hallways, bathrooms, staff offices, nurse stations, and break areas.
The need for the SteraMist technology has never been greater, with medical facilities seeking a safeguard to act as a secure medical haven for patients experiencing mental health and behavioral challenges. Coronavirus has elevated disinfection protocols adopted by the medical community and will continue to evolve well beyond the pandemic, with further scrutiny placed on other harmful pathogens prevalent in medical environments such as MRSA, C. diff, and C. auris. With a second wave rise in COVID infection rates alongside the looming influenza season, diagnoses and medical treatments may be complicated and sheer volume may challenge healthcare structures.
Patient waiting rooms, lobby/common areas, clinical assessment, in-patient rooms, therapy and activity areas maintain hard deadline limitations for disinfection execution. SteraMist’s quick application, lack of toxic byproducts, and nonexistent residue creates the perfect solution to bring high traffic areas back into circulation quickly to avoid disrupting regular patient care.
Dr. Halden Shane, CEO of TOMI, stated that, “Not all COVID-19 disinfectants are created the same, and unlike a majority of the other options, SteraMist does not use harmful chemicals or damage the most delicate of electronics, equipment or fixtures. SteraMist is rooted in scientific evidence, developed under a DARPA grant and is the first ever EPA-registered Hospital-Healthcare and General Disinfectant equipment and solution combination. SteraMist can be trusted for its efficacy and non-caustic impact to patient care environments.”
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
For additional information, please visit http://www.tomimist.com/ or contact us at info@tomimist.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.
INVESTOR RELATIONS CONTACT
John Nesbett/Jennifer Belodeau
IMS Investor Relations
jnesbett@imsinvestorrelations.com
